Item 5.02. Departure of Directors or Certain Officers; Election of Directors;


           Appointment of Certain Officers; Compensatory Arrangements of Certain
           Officers.

On January 16, 2023, Ernest De Paolantonio, the Chief Financial Officer of Journey Medical Corporation (the "Company") provided notice to the Company of his resignation, effective January 27, 2023. Mr. De Paolantonio will consult with and advise the Company until March 31, 2023.

In connection with such resignation, Joseph Benesch, age 56, the Company's Corporate Controller, was appointed as the Company's interim Chief Financial Officer, effective January 27, 2023. Mr. Benesch's compensation has not changed as a result of this appointment. Any changes to Mr. Benesch's compensation package, if any, will be determined by the Company's Board of Directors upon recommendation of its Compensation Committee.

Mr. Benesch was hired as the Company's Corporate Controller in November 2021. He previously served as the Principal Accounting Officer, Vice President and Corporate Controller of Teligent Pharma Inc., a specialty generic pharmaceutical company, and Corporate Controller of Torrent Pharmaceuticals Ltd., a U.S. subsidiary of the Torrent Group, a multinational pharmaceutical company. Before joining Torrent Pharmaceuticals Ltd., he held senior financial management positions from corporate controller to Vice President of Finance at Savient Pharmaceuticals, Adare Pharmaceuticals, Inc. and Edenbridge Pharmaceuticals. He began his career in the public accounting sector at Baker Tilly Virchow Krause, LLP, and Ernst and Young Global Limited, working with a diverse client base. He is a Certified Public Accountant with an active license. Mr. Benesch is a graduate of Wilkes University where he earned a BA in accounting.

No family relationships exist between Mr. Benesch and any of the Company's directors or executive officers. There are no arrangements or understandings between Mr. Benesch and any other person pursuant to which Mr. Benesch was selected as the Company's interim Chief Financial Officer, nor are there any transactions to which the Company is or was a participant and in which Mr. Benesch has a material interest subject to disclosure under Item 404(a) of Regulation S-K.

A press release related to Mr. De Paolantonio's departure and Mr. Benesch's appointment is attached as Exhibit 99.1 to this report and is incorporated by reference to this Item 5.02.

Item 9.01. Financial Statements and Exhibits.






(d) Exhibits.

The following exhibits are furnished herewith:





Exhibit
Number     Description
  99.1       Press Release, dated January 20, 2023.
           Cover Page Interactive Data File, formatted in Inline Extensible
104        Business Reporting Language (iXBRL).

© Edgar Online, source Glimpses